Interestingly, despite patients with K-ras wild-type tumours could benefit from cetuximab/panitumumab, when these patients were treated with oxaliplatin-based chemotherapy plus bevacizumab plus cetuximab/panitumumab, no additional benefit was seen over chemotherapy plus bevacizumab (Hecht et al, 2009; Tol et al, 2009). The gene discussed is KRAS; the disease is neoplasm.